Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
03:38am, Monday, 22'nd Dec 2025
The pole position in the GLP-1 weight loss space is currently held by Eli Lilly. Novo Nordisk was the early leader, showing that being first doesn't always mean you stay at the head of the pack.
Better Buy in 2026: Pfizer or Merck?
03:00pm, Friday, 19'th Dec 2025
Pfizer has at least two key candidates in the pipeline that look like future winners. Merck has launched several products in preparation for a massive upcoming patent cliff.
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
11:50am, Friday, 19'th Dec 2025
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound
11:45am, Friday, 19'th Dec 2025
Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worryi
Trump to announce new drug-pricing deals later today
10:45am, Friday, 19'th Dec 2025
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Addenda Capital Inc. Boosts Stock Position in Pfizer Inc. $PFE
03:22am, Friday, 19'th Dec 2025
Addenda Capital Inc. grew its holdings in shares of Pfizer Inc. (NYSE: PFE) by 26.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fu
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now
08:30pm, Thursday, 18'th Dec 2025
These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters.
Better Buy in 2026: Pfizer or Eli Lilly?
11:45am, Thursday, 18'th Dec 2025
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer's acquisitions haven't paid off yet and the company is still struggling to grow its sales.
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
10:00am, Thursday, 18'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday,
Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun
06:58am, Thursday, 18'th Dec 2025
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal
Pfizer Stock Can Sink More. Here Is How
02:36pm, Wednesday, 17'th Dec 2025
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
If I Could Only Buy and Hold a Single Stock, This Would Be It
11:47am, Wednesday, 17'th Dec 2025
Lower demand for COVID-19 treatments has been hurting Pfizer's revenue. Pfizer also has major products losing patent protection over the next couple of years.
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
11:01am, Wednesday, 17'th Dec 2025
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back
10:14am, Wednesday, 17'th Dec 2025
Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this mon
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
06:45am, Wednesday, 17'th Dec 2025
PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with
